China Tax for Healthcare & Life Sciences Industry - Issue 2, March 2014
Transfer pricing is in the spotlight for our second issue of the China Tax for the Healthcare and Life Sciences Industry series. We have outlined the specific concerns of pharmaceutical and medical device companies operating in China regarding their transfer pricing arrangements, as well as our key recommendations for:
© 2020 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in China, KPMG, a Macau partnership and KPMG, a Hong Kong partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited ("KPMG International"), a private English company limited by guarantee. All rights reserved. The KPMG name and logo are registered trademarks or trademarks of KPMG International.
For more detail about the structure of the KPMG global organisation please visit https://home.kpmg/governance.